SEC Form 4 · accession 0001209191-19-011994
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Reshma Kewalramani
Officer — EVP and CMO
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 19, 2019 | S | 1,186 | $186.75 | D | 14,038 | D | |
| Common StockF3,F4 | Feb 19, 2019 | S | 202 | $187.27 | D | 13,836 | D | |
| Common StockF3,F5 | Feb 19, 2019 | S | 100 | $188.49 | D | 13,736 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $186.75 (range $186.10 to $187.05).
- F3Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $187.27 (range $187.11 to $187.49).
- F5Open market sales reported on this line occurred at a weighted average price of $188.49 (range $188.36 to $188.70).